Secondary analysis of TRIANGLE: in 511 younger, untreated mantle cell lymphoma responders on ibrutinib-containing therapy with or without ASCT, non-randomised rituximab maintenance was associated with longer 4-year PFS (85% v 73%; 90% v 75%) but more grade 3–5 infections.
Secondary analysisn = 511
Ladetto et al. Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial